Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
397 search results for:

Advanced lung cancer 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 01-08-2022 | Non-small-cell lung cancer | Adis Journal Club | Article
    Targeted Oncology

    Randomized Versus Real-World Evidence on the Efficacy and Toxicity of Checkpoint Inhibitors in Cancer in Patients with Advanced Non-small Cell Lung Cancer or Melanoma: A Meta-analysis

    Objective The aim of this study was to compare the efficacy and toxicity of checkpoint inhibitors between RCTs and RWE studies in patients with advanced non-small cell lung cancer (NSCLC) or melanoma.

  2. 18-11-2017 | Non-small-cell lung cancer | Article

    Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

    Soria JC et al.  N Engl J Med  2018; 378(2): 113-125. doi:10.1056/NEJMoa1713137

  3. 28-03-2018 | Non-small-cell lung cancer | Article

    ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer

    Nestle U et al.  Radiother Oncol  2018; 127(1): 1-5. doi:10.1016/j.radonc.2018.02.023

  4. 12-03-2018 | Durvalumab | Article

    Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

    Garassino MC et al. Lancet Oncol 2018; 19(4): 521–536. doi:10.1016/S1470-2045(18)30144-X

  5. 13-06-2017 | Atezolizumab | Article

    Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)

    Peters S et al.  J Clin Oncol 2017; 35(24): 781-2789. doi: 10.1200/JCO.2016.71.9476

  6. 10-05-2017 | Celecoxib | Article

    Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance)

    Edelman MJ et al.  J Clin Oncol  2017; 35(19): 2184-2192. doi: 10.1200/JCO.2016.71.3743

  7. 31-10-2016 | Intensity modulated radiation therapy | Article

    Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non–Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial

    Chun SG et al.  J Clin Oncol  2017; 35(1): 56-62. doi:10.1200/JCO.2016.69.1378

  8. 10-10-2016 | Pembrolizumab | Article

    Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

    Langer CJ et al. Lancet Oncol 2016; 17(11): 1497–1508. doi: 10.1016/S1470-2045(16)30498-3

  9. 22-09-2023 | KRAS inhibitors | News | Article

    Novel KRAS inhibitor elicits ‘durable responses’ in KRAS G12C mutation-positive tumors

    The novel KRAS inhibitor divarasib has shown promise in previously treated patients with advanced solid tumors harboring a KRAS G12C mutation.

    Author:
    Shreeya Nanda
    Published in:
    N Engl J Med 2023; 389 : 710–721
  10. 28-07-2023 | Non-small-cell lung cancer | News | Article

    Atezolizumab may be beneficial for platinum-ineligible advanced NSCLC

    First-line treatment with atezolizumab significantly improves the overall survival of platinum-ineligible patients with locally advanced or metastatic non-small-cell lung cancer relative to chemotherapy.

    Author:
    Shreeya Nanda
    Published in:
    Lancet 2023; doi:10.1016/S0140-6736(23)00774-2 Lancet 2023; doi:10.1016/S0140-6736(23)00807-3
  11. 07-07-2017 | Non-small-cell lung cancer | Article

    Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial

    Salavati A et al. Eur J Nucl Med Mol Imaging 2017; 44: 1969. doi:10.1007/s00259-017-3753-x

  12. 06-06-2023 | Non-small-cell lung cancer | Conference coverage | Article
    ASCO 2023

    ADAURA demonstrates OS gain with adjuvant osimertinib in early-stage NSCLC

    Adjuvant treatment with osimertinib significantly prolongs overall survival relative to placebo in people with EGFR -mutated, early-stage non-small-cell lung cancer, show trial results.

    Author:
    Shreeya Nanda
    Published in:
    2023 ASCO Annual Meeting; Chicago, Illinois, USA: 2–6 June N Engl J Med 2023; doi:10.1056/NEJMoa2304594
  13. 09-02-2023 | Non-small-cell lung cancer | News | Article

    Real-world data show ‘modest’ survival gains with immunotherapy in older NSCLC patients

    The overall survival benefit offered by immune checkpoint inhibitors in people with advanced non-small-cell lung cancer varies by age, suggests a real-world study.

    Author:
    Shreeya Nanda
    Published in:
    JAMA Oncol 2023; doi:10.1001/jamaoncol.2022.6901 JAMA Oncol 2023; doi:10.1001/jamaoncol.2022.6867
  14. 26-01-2023 | Non-small-cell lung cancer | News | Article

    Adding camrelizumab to chemo prolongs OS of patients with advanced nonsquamous NSCLC

    An updated analysis of the CameL trial has shown a significant improvement in overall survival with the addition of camrelizumab to chemotherapy in treatment-naïve Chinese patients with advanced nonsquamous non-small-cell lung cancer.

    Author:
    Shreeya Nanda
    Published in:
    J Thorac Oncol 2023; doi:10.1016/j.jtho.2022.12.017
  15. 14-03-2023 | EMA | News | Article
    approvalsWatch

    EMA recommends extension to cemiplimab indication

    Click through for more information about this lung cancer recommendation

    Author:
    Shreeya Nanda
  16. 12-01-2023 | Non-small-cell lung cancer | News | Article
    News in brief

    CROWN update confirms long-term lorlatinib PFS benefit

    Lorlatinib offers a “durable benefit” for the first-line treatment of advanced ALK -positive non-small-cell lung cancer, indicates a 3-year update from the CROWN trial.

    Author:
    Lynda Williams
    Published in:
    Lancet Resp Med 2023; doi:10.1016/S2213-2600(22)00437-4
  17. 01-02-2023 | FDA | News | Article
    approvalsWatch

    FDA approves elacestrant, adds indication for pembrolizumab

    Details of these breast and lung cancer decisions available here

    Author:
    Shreeya Nanda
  18. 05-09-2022 | Lung cancer | News | Article

    First-line cemiplimab prolongs advanced NSCLC survival irrespective of PD-L1 expression

    Adding cemiplimab to first-line platinum-doublet chemotherapy significantly improves outcomes for patients with advanced non-small-cell lung cancer, regardless of tumor PD-L1 expression or histology, EMPOWER-Lung 3 study data show.

    Author:
    Laura Cowen
    Published in:
    Nature Med 2022; doi:10.1038/s41591-022-01977-y
  19. 28-10-2022 | Non-small-cell lung cancer | News | Article

    Real-world study adds support for osimertinib for uncommon EGFR mutations

    Osimertinib elicits high rates of systemic and intracranial response in people with advanced non-small-cell lung cancer harboring uncommon EGFR mutations, say the authors of the real-world UNICORN study.

    Author:
    Shreeya Nanda
    Published in:
    J Thorac Oncol 2022; doi:10.1016/j.jtho.2022.10.004

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.